Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: A prospective study

Journal of Rheumatology

Volumn 36, Issue 11, 2009, Pages 2476-2480

  Petri, Michelle ^a   Singh, Sukhminder ^a   Tesfasyone, Hanna ^a   Malik, Ashima ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

British Isles Lupus Assessment Group; Flare; Lupus

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE EXACERBATION; ETHNICITY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEROLOGY; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 70450189501     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090019     Document Type: Article

References (29)

1. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-1118
2. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992;19:608-611
3. Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000;27:664-670 (Pubitemid 30151343)
4. Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of Systemic Lupus Activity Measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001;10:405-409 (Pubitemid 32578615)
5. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992;19:53-59
6. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994;21:1468-1471 (Pubitemid 24261530)
7. Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman D. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993;20:657-660 (Pubitemid 23138854)
8. Ruiz-Irastorza G, Khamashta MA, Gordon C, Lockshin MD, Johns KR, Sammaritano L, et al. Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale. Arthritis Rheum 2004;51:78-82. (Pubitemid 38222286)
9. Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:549-554
10. Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, Bombardieri S. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 200;9:445-450
11. Bombardieri S, Vitali C, Caponi L, Manca L, Bencivelli W. Activity criteria in systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:S45-8.
12. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004 - Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology 2009;48:691-695 Epub 2009 Apr 24.
13. Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerised index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988;69:927-937
14. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-458 (Pubitemid 23223653)
15. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996;55:756-760 (Pubitemid 26354438)
16. Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000;27:664-670 (Pubitemid 30151343)
17. Isenberg DA, Gordon C. From BILAG to BLIPS - disease activity assessment in lupus past, present and future. Lupus 2000;9:651-654 (Pubitemid 32011789)
18. Ehrenstein MR, Conroy SE, Heath J, Latchman DS, Isenberg DA. The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view. Br J Rheumatol 1995;34:257-260
19. Gordon C, Sutcliffe N, Skan J, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003;42:1372-1379 (Pubitemid 37407029)
20. Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS, et al. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006;54:3300-3305
21. Danowski A, Magder L, Petri M. Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. J Rheumatol 2006;33:57-60. (Pubitemid 43054280)
22. Kaufman LD, Gomez-Reino JJ, Heinicke MH, Gorevic PD. Male lupus: retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature. Semin Arthritis Rheum 1989;18:189-197
23. Petri M, Perez-Gutthann S, Longenecker JC, Hochberg MC. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991;91:345-353
24. Ho A, Magder L, Barr S, Petri M. Decreases in anti-double stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342-2349 (Pubitemid 32977502)
25. Ho A, Magder LS, Barr SG, Petri MA. A decrease in complement is associated with increased renal and hematologic flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2350-2357 (Pubitemid 32977503)
26. Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:3623-3632 (Pubitemid 44737174)
27. Swaak AJG, Gorenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45:359-366 (Pubitemid 16121710)
28. Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CGM. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990;33:634-643 (Pubitemid 20166564)
29. Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-454 (Pubitemid 36278013)